A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.

Abstract

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, has been approved as a treatment in persons with active relapsing-remitting multiple sclerosis (RRMS). Real-world data in middle east is very limited. We aimed to evaluate the effectiveness and safety of alemtuzumab in a real-world clinical setting. This observational, registry based study assessed persons with multiple sclerosis (PwMS) who were treated with alemtuzumab and completed at least follow up one year after second course. Baseline clinical and radiological characteristics within one year prior to alemtuzumab initiation were collected. The relapse rate, disability measures, radiological activity and adverse events at last follow-up visits were assessed. Data of seventy-three persons with multiple sclerosis (MS) was analyzed, of which 53 (72.6%) were females. Mean age and mean disease duration were 34.25±7.62 and 9.23±6.20 years respectively. Alemtuzumab was started in32(43.8%)naïve patientsdue tohighly active disease and in 25 (34.2%) (PwMS) who were on prior therapies andin 16 (22%) patients due to adverse events on prior medications. Mean follow-up period was 4±1.67 years. In the last follow-up visits, most of our cohort was relapse free (79.5% vs. 17.8%; p<0.001) compared to baseline before alemtuzumab treatment while mean EDSS score was reduced (2.21±2.15vs. 2.41±1.85; p<0.059). The proportion of PwMS who had MRI activity (new T2/ Gd-enhancing) lesions were significantly reduced compared to baseline (15.1% vs. 82.2%; p<0.001). NEDA-3 was achieved in 57.5% of (PwMS). NEDA-3 was significantly better in naïve patients (78% versus. 41.5%; p<0.002) and in patients with disease duration < 5 years, (82.6% v 43.2%; p<0.002). Several adverse events such as infusion reactions (75.3%), autoimmune thyroiditis (16.4%) and glomerulonephritis (2.7%) were reported. The effectiveness and safety profile of alemtuzumab in this cohort were consistent with data of clinical trials. Early initiation of Alemtuzumab is associated with favorable outcome.